Firebrick Pharma announced that it has launched Nasodine povidone-iodine nasal spray in the US via direct sales through a web site. The company said that it will not make any therapeutic claims so that the nasal spray will not require FDA approval. For now, Firebrick said, Nasodine will be marketed as a “nasal hygiene” product and will be available only on a US web site. The company added that it hopes to sell the nasal spray in US pharmacies in the future and that it plans to develop other products to add to the Nasodine line.
The company had been developing Nasodine for the treatment of the common cold; however, it later changed strategy, and in January 2024, the company announced that it had withdrawn its appeal of a refusal by Australia’s TGA to approve the nasal spray for that indication.
Firebrick Executive Chairman Peter Molloy commented, “Nasodine will be the only PVP-iodine nasal spray in the US that is supported by proven safety in clinical trials and a growing list of peer-reviewed publications. Our position has always been that if we can make Nasodine available, people will use it. In a post-COVID world, where everyone is concerned about nasal hygiene, we believe Nasodine is the answer.”
Read the Firebrick Pharma press release.
